← Human Trials & Peer-Reviewed Studies
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.
Plain-language guide to PMID 38085047 (2024): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 2021, participants, multiple sclerosis.
Key Facts
- PMID
- 38085047
- Journal
- Brain : a journal of neurology
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Butzkueven H et al. (28 authors)
- DOI
- 10.1093/brain/awad409
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of multiple sclerosis in this randomized controlled trial publication.
Low serum levels of 25-hydroxyvitamin D [25(OH)D] and low sunlight exposure are known risk factors for the development of multiple sclerosis.
Between 2013 and 2021, the researchers enrolled 204 participants.
Who Took Part
The study group was 2021, participants.
PubMed tags the participants as both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
What Was Measured
Low serum levels of 25-hydroxyvitamin D [25(OH)D] and low sunlight exposure are known risk factors for the development of multiple sclerosis.
The main study outcome was conversion to clinically definite multiple sclerosis based on the 2010 McDonald criteria defined as either a clinical relapse or new brain MRI T2 lesion development.
PubMed files the paper under topics including Calcifediol, Cholecalciferol, Demyelinating Diseases, Multiple Sclerosis, Vitamin D and Vitamins.
The authors tagged it with the keywords clinical trial.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 2021, participants in people with multiple sclerosis.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2024 (Brain : a journal of neurology), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Multiple sclerosis research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.